


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Please amend the claims as follows:

Claim 1. (Currently Amended) ~~Compounds~~ A compound of the formula I



in which

R¹ is H, A or SO₂A,

A is straight-chain or branched alkyl having from 1 to 10 carbon atoms, alkenyl having from 2 to 10 carbon atoms or alkoxyalkyl having from 2 to 10 carbon atoms, and

D-E is R²C=CR⁴ or R²R³C-CR⁴R⁵,

in which

R², R³, R⁴ and R⁵ are selected, independently, from

H, A, cycloalkyl having from 3 to 7 carbon atoms, Hal, CH₂Hal, CH(Hal)₂, C(Hal)₃, NO₂, (CH₂)_nCN, (CH₂)_nN(R⁶)₂, (CH₂)_nN(R⁶)Ar, (CH₂)_nN(R⁶)Het, (CH₂)_nN(Ar)₂, (CH₂)_nN(Het)₂, (CH₂)_nCOOR⁶, (CH₂)_nCOOAr, (CH₂)_nCOOHet, (CH₂)_nCON(R⁶)₂, (CH₂)_nCON(R⁶)Ar, (CH₂)_nCON(R⁶)Het, (CH₂)_nCON(Ar)₂, (CH₂)_nCON(Het)₂, (CH₂)_nNR⁶COR⁶, (CH₂)_nNR⁶CON(R⁶)₂, (CH₂)_nNR⁶SO₂A, (CH₂)_nSO₂N(R⁶)₂, (CH₂)_nSO₂NR⁶(CH₂)_mAr,

$(\text{CH}_2)_n\text{SO}_2\text{NR}^6(\text{CH}_2)_m\text{Het}$, $(\text{CH}_2)_n\text{S}(\text{O})_w\text{R}^6$, $(\text{CH}_2)_n\text{S}(\text{O})_w\text{Ar}$,
 $(\text{CH}_2)_n\text{S}(\text{O})_w\text{Het}$, $(\text{CH}_2)_n\text{OOCR}^6$, $(\text{CH}_2)_n\text{Het}$, $(\text{CH}_2)_n\text{Ar}$, $(\text{CH}_2)_n\text{COR}^6$,
 $(\text{CH}_2)_n\text{CO}(\text{CH}_2)_m\text{Ar}$, $(\text{CH}_2)_n\text{CO}(\text{CH}_2)_m\text{Het}$, $(\text{CH}_2)_n\text{COO}(\text{CH}_2)_m\text{Ar}$,
 $(\text{CH}_2)_n\text{COO}(\text{CH}_2)_m\text{Het}$, $(\text{CH}_2)_n\text{OR}^6$, $(\text{CH}_2)_n\text{O}(\text{CH}_2)_m\text{Ar}$,
 $(\text{CH}_2)_n\text{O}(\text{CH}_2)_m\text{Het}$, $(\text{CH}_2)_n\text{SR}^6$, $(\text{CH}_2)_n\text{S}(\text{CH}_2)_m\text{Ar}$,
 $(\text{CH}_2)_n\text{S}(\text{CH}_2)_m\text{Het}$, $(\text{CH}_2)_n\text{N}(\text{R}^6)(\text{CH}_2)_m\text{Ar}$, $(\text{CH}_2)_n\text{N}(\text{R}^6)(\text{CH}_2)_m\text{Het}$,
 $(\text{CH}_2)_n\text{SO}_2\text{N}(\text{R}^6)(\text{CH}_2)_m\text{Ar}$, $(\text{CH}_2)_n\text{N}(\text{R}^6)\text{SO}_2(\text{CH}_2)_m\text{Ar}$,
 $(\text{CH}_2)_n\text{SO}_2\text{N}(\text{R}^6)(\text{CH}_2)_m\text{Het}$, $(\text{CH}_2)_n\text{N}(\text{R}^6)\text{SO}_2(\text{CH}_2)_m\text{Het}$,
 $(\text{CH}_2)_n\text{CON}(\text{R}^6)(\text{CH}_2)_m\text{Ar}$, $(\text{CH}_2)_n\text{N}(\text{R}^6)\text{CO}(\text{CH}_2)_m\text{Ar}$,
 $(\text{CH}_2)_n\text{CON}(\text{R}^6)(\text{CH}_2)_m\text{Het}$, $(\text{CH}_2)_n\text{N}(\text{R}^6)\text{CO}(\text{CH}_2)_m\text{Het}$, $\text{CH}=\text{N}-\text{OA}$,
 $\text{CH}_2\text{CH}=\text{N}-\text{OA}$, $(\text{CH}_2)_n\text{NHOA}$, $(\text{CH}_2)_n\text{CH}=\text{N}-\text{Het}$, $(\text{CH}_2)_n\text{OCOR}^6$,
 $(\text{CH}_2)_n\text{OC}(\text{O})\text{N}(\text{R}^6)_2$, $(\text{CH}_2)_n\text{OC}(\text{O})\text{NR}^6(\text{CH}_2)_m\text{Ar}$,
 $(\text{CH}_2)_n\text{OC}(\text{O})\text{NR}^6(\text{CH}_2)_m\text{Het}$, $(\text{CH}_2)_n\text{NR}^6\text{COOR}^6$,
 $(\text{CH}_2)_n\text{NR}^6\text{COO}(\text{CH}_2)_m\text{Ar}$, $(\text{CH}_2)_n\text{NR}^6\text{COO}(\text{CH}_2)_m\text{Het}$,
 $(\text{CH}_2)_n\text{N}(\text{R}^6)\text{CH}_2\text{CH}_2\text{OR}^6$, $(\text{CH}_2)_n\text{N}(\text{R}^6)\text{CH}_2\text{CH}_2\text{OCF}_3$,
 $(\text{CH}_2)_n\text{N}(\text{R}^6)\text{C}(\text{R}^6)\text{HCOOR}^6$, $(\text{CH}_2)_n\text{N}(\text{R}^6)\text{CH}_2\text{COHet}$,
 $(\text{CH}_2)_n\text{N}(\text{R}^6)\text{CH}_2\text{Het}$, $(\text{CH}_2)_n\text{N}(\text{R}^6)\text{CH}_2\text{CH}_2\text{N}(\text{R}^6)\text{CH}_2\text{COOR}^6$,
 $(\text{CH}_2)_n\text{N}(\text{R}^6)\text{CH}_2\text{CH}_2\text{N}(\text{R}^6)_2$, $\text{CH}=\text{CHCOOR}^6$, $\text{CH}=\text{CHCH}_2\text{NR}^6\text{Het}$,
 $\text{CH}=\text{CHCH}_2\text{N}(\text{R}^6)_2$, $\text{CH}=\text{CHCH}_2\text{OR}^6$, $(\text{CH}_2)_n\text{N}(\text{COOR}^6)\text{COOR}^6$,
 $(\text{CH}_2)_n\text{N}(\text{CONH}_2)\text{COOR}^6$, $(\text{CH}_2)_n\text{N}(\text{CONH}_2)\text{CONH}_2$,
 $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{COOR}^6)\text{COOR}^6$, $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{CONH}_2)\text{COOR}^6$,
 $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{CONH}_2)\text{CONH}_2$, $(\text{CH}_2)_n\text{CHR}^6\text{COR}^6$,
 $(\text{CH}_2)_n\text{CHR}^6\text{COOR}^6$, $(\text{CH}_2)_n\text{CHR}^6\text{CH}_2\text{OR}^6$, $(\text{CH}_2)_n\text{OCN}$ or
 $(\text{CH}_2)_n\text{NCO}$, in which

R^6 is selected, independently, from H, A or cycloalkyl having from 3 to 7 carbon atoms,

Het is a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic radical which is unsubstituted or mono- or poly-substituted by A, Hal, NO_2 , CN, OR^6 , $\text{N}(\text{R}^6)_2$, COOR^6 , $\text{CON}(\text{R}^6)_2$,

NR^6COR^6 , $\text{NR}^6\text{CON}(\text{R}^6)_2$, $\text{NR}^6\text{SO}_2\text{A}$, COR^6 , $\text{SO}_2\text{N}(\text{R}^6)_2$, $\text{S}(\text{O})_w\text{A}$ and/or OOCR^6 ,

Ar is an aromatic hydrocarbon radical having from 6 to 14 carbon atoms which is unsubstituted or mono- or polysubstituted by A, Hal, NO_2 , CN, OR^6 , $\text{N}(\text{R}^6)_2$, COOR^6 , $\text{CON}(\text{R}^6)_2$, NR^6COR^6 , $\text{NR}^6\text{CON}(\text{R}^6)_2$, $\text{NR}^6\text{SO}_2\text{A}$, COR^6 , $\text{SO}_2\text{N}(\text{R}^6)_2$, $\text{S}(\text{O})_w\text{A}$ and/or OOCR^6 ,

w is 0, 1, 2 or 3, and

n and m, independently of one another, are 0, 1, 2, 3, 4 or 5;

X^1 is $(\text{CHR}^7)_g$ or $(\text{CHR}^7)_h\text{-Q-}(\text{CHR}^8)_k$, in which

Q is selected from O, S, N-R^6 , $(\text{O-CHR}^7)_g$, $(\text{CHR}^7\text{-O})_g$, $\text{CR}^9=\text{CR}^{10}$, $(\text{O-CHR}^9\text{CHR}^{10})_g$, $(\text{CHR}^9\text{CHR}^{10}\text{-O})_g$, C=O, C=S, C=NR^6 , $\text{CH}(\text{OR}^6)$, $\text{C}(\text{OR}^6)(\text{OR}^6)$, C(=O)O , OC(=O) , OC(=O)O , $\text{C(=O)N}(\text{R}^6)$, $\text{N}(\text{R}^6)\text{C(=O)}$, $\text{C(=S)N}(\text{R}^6)$, $\text{N}(\text{R}^6)\text{C(=S)}$, $\text{OC(=O)N}(\text{R}^6)$, $\text{N}(\text{R}^6)\text{C(=O)O}$, CH=N-O , CH=N-NR^6 , OC(O)NR^6 , $\text{NR}^6\text{C(O)O}$, S=O, SO_2 , SO_2NR^6 and NR^6SO_2 ,

g is 1, 2, 3, 4, 5 or 6,

h and k, independently of one another, are 0, 1, 2, 3, 4, 5 or 6, and

R^7 , R^8 , R^9 , R^{10} and R^{12} , independently of one another, are as defined for R^2 to R^5 ;

p is 0, 1, 2 or 3,

E is H, A, (CH₂)_nHet, (CH₂)_nAr or cycloalkyl having from 3 to 7 carbon atoms,

G is an optionally substituted alkylene radical having from 1 to 4 carbon atoms, where the substituents are selected from the meanings indicated for R⁴,

or

E and

G, together with the N atom to which they are bonded, are an unsubstituted or substituted 5-, 6- or 7-membered, mono- or bicyclic heterocyclic radical, which may have 1, 2 or 3 further heteroatoms selected from N, O and S,

X² is a bond or is selected, independently, from the meanings indicated for X¹,

Z is H or is a saturated, mono- or polyethylenically unsaturated or aromatic carbocyclic radical having from 5 to 10 carbon atoms or a saturated, mono- or polyethylenically unsaturated or aromatic heterocyclic radical having from 4 to 9 carbon atoms, where the carbocyclic or heterocyclic radical may be mono- or polysubstituted, where the substituents are selected, independently of one another, from the meanings of R² to R⁵ other than H, and where the heterocyclic radical contains from 1 to 4 heteroatoms selected, independently of one another, from N, O and S,

and

Hal is F, Cl, Br or I,

and or a pharmaceutically usable derivatives, salts, solvates and stereoisomers and mixtures acceptable salt, solvate, stereoisomer or mixture thereof.

Claim 2. (Currently Amended) Compounds The compound of the formula I according to Claim 1, in which

A is straight-chain alkyl having from 1 to 4 carbon atoms or branched alkyl having from 3 to 6 carbon atoms, and

D-E is $R^2C=CR^4$ or $R^2R^3C-CR^4R^5$, in particular $R^2C=CR^4$, in which R^2 , R^3 and R^5 are selected, independently, from H, A and cycloalkyl having from 3 to 7 carbon atoms,

and

R^4 is Hal, CH_2Hal , $CH(Hal)_2$, $C(Hal)_3$, NO_2 , $(CH_2)_nCN$, $(CH_2)_nCOOR^6$, $(CH_2)_nCON(R^6)_2$, $(CH_2)_nNR^6COR^6$, $(CH_2)_nNR^6CON(R^6)_2$, $(CH_2)_nNR^6SO_2A$, $(CH_2)_nSO_2N(R^6)_2$, $(CH_2)_nS(O)_wA$, $(CH_2)_nOOCR^6$, $(CH_2)_nCOR^6$, $(CH_2)_nCO(CH_2)_mAr$, $(CH_2)_nCO(CH_2)_mHet$, $(CH_2)_nCOO(CH_2)_mAr$, $(CH_2)_nCOO(CH_2)_mHet$, $(CH_2)_nOR^6$, $(CH_2)_nO(CH_2)_mAr$, $(CH_2)_nO(CH_2)_mHet$, $(CH_2)_nSR^6$, $(CH_2)_nS(CH_2)_mAr$, $(CH_2)_nS(CH_2)_mHet$, $(CH_2)_nN(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)(CH_2)_mHet$, $(CH_2)_nSO_2N(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)SO_2(CH_2)_mAr$, $(CH_2)_nSO_2N(R^6)(CH_2)_mHet$, $(CH_2)_nN(R^6)SO_2(CH_2)_mHet$, $(CH_2)_nCON(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)CO(CH_2)_mAr$, $(CH_2)_nCON(R^6)(CH_2)_mHet$, $(CH_2)_nN(R^6)CO(CH_2)_mHet$, $(CH_2)_nN(R^6)_2$, $(CH_2)_nOCOR^6$, $(CH_2)_nOC(O)N(R^6)_2$, $(CH_2)_nOC(O)NR^6(CH_2)_mAr$, $(CH_2)_nOC(O)NR^6(CH_2)_mHet$, $(CH_2)_nNR^6COOR^6$, $(CH_2)_nNR^6COO(CH_2)_mAr$, $(CH_2)_nNR^6COO(CH_2)_mHet$, $(CH_2)_nN(R^6)CH_2CH_2OR^6$, $(CH_2)_nN(R^6)CH_2CH_2OCF_3$,

$(\text{CH}_2)_n\text{N}(\text{R}^6)\text{C}(\text{R}^6)\text{HCOOR}^6$, $(\text{CH}_2)_n\text{N}(\text{R}^6)\text{CH}_2\text{COHet}$,
 $(\text{CH}_2)_n\text{N}(\text{R}^6)\text{CH}_2\text{Het}$, $(\text{CH}_2)_n\text{N}(\text{R}^6)\text{CH}_2\text{CH}_2\text{N}(\text{R}^6)\text{CH}_2\text{COOR}^6$,
 $(\text{CH}_2)_n\text{N}(\text{R}^6)\text{CH}_2\text{CH}_2\text{N}(\text{R}^6)_2$, $\text{CH}=\text{CHCOOR}^6$,
 $(\text{CH}_2)_n\text{N}(\text{COOR}^6)\text{COOR}^6$, $(\text{CH}_2)_n\text{N}(\text{CONH}_2)\text{COOR}^6$,
 $(\text{CH}_2)_n\text{N}(\text{CONH}_2)\text{CONH}_2$, $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{COOR}^6)\text{COOR}^6$,
 $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{CONH}_2)\text{COOR}^6$, $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{CONH}_2)\text{CONH}_2$,
 $(\text{CH}_2)_n\text{CHR}^6\text{COR}^6$, $(\text{CH}_2)_n\text{CHR}^6\text{COOR}^6$ or $(\text{CH}_2)_n\text{CHR}^6\text{CH}_2\text{OR}^6$
~~and in particular Hal, CH₂Hal, CH(Hal)₂, C(Hal)₃, NO₂, (CH₂)_nCN,~~
~~(CH₂)_nCOOR⁶, (CH₂)_nCON(R⁶)₂, (CH₂)_nSO₂N(R⁶)₂ or~~
~~(CH₂)_nS(O)_wA,~~

m is 0, 1, 2, 3, 4 or 5 and

n is ~~0, 1, 2 or 3 and~~
in particular 0 or 1;

X¹ is (CHR⁷)_g or Q-(CHR⁸)_k, in which

Q is selected from O, S, N-R⁶, (O-CHR⁷)_g, (CHR⁷-O)_g, CR⁹=CR¹⁰,
(O-CHR⁹CHR¹⁰)_g, (CHR⁹CHR¹⁰-O)_g, C=O, C=S, C=NR⁶,
C(OR⁶)(OR⁶), C(=O)O, OC(=O), OC(=O)O, C(=O)N(R⁶),
N(R⁶)C(=O), OC(=O)N(R⁶), N(R⁶)C(=O)O, CH=N-O, CH=N-NR⁶,
OC(O)NR⁶, NR⁶C(O)O, S=O, SO₂, SO₂NR⁶ and NR⁶SO₂,

g is ~~1, 2, 3, 4, 5 or 6 and in particular~~ 2, 3 or 4,

k is ~~0, 1, 2, 3, 4, 5 or 6 and in particular~~ 1, 2 or 3, and

R⁷, R⁸, R⁹ and R¹⁰ are selected, independently, from the meanings
indicated for R² to R⁵;

X^2 is a bond or independently is $(CHR^7)_g$ or $Q-(CHR^8)_k$, in which


Q is selected from O, S, $N-R^6$, $(O-CHR^7)_g$, $(CHR^7-O)_g$, $(O-CHR^9CHR^{10})_g$, $(CHR^9CHR^{10}-O)_g$, C=O, $CH(OR^6)$, $C(=O)O$, $OC(=O)$, $C(=O)N(R^6)$, $N(R^6)C(=O)$, S=O, SO_2 , SO_2NR^6 and NR^6SO_2 , where

g in X^2 is preferably 1 or 2 and k in X^2 is preferably 0 or 1, and

R^{12} is selected, independently, from the meanings of R^4 other than H and in particular, independently, is ~~F, Cl, Br, I, CN, NO_2 , NH_2 , CF_3 , OCF_3 , $C(NH)NOH$ or SO_2CH_3 ,~~

and or a pharmaceutically usable derivatives, salts, solvates and stereoisomers and mixtures acceptable salt, solvate, stereoisomer or mixture thereof.

Claim 3. (Currently Amended) Compounds The compound according to Claim 1, selected from compounds of the formula Ia,



in which

R^1 , D-E and Z are as defined above, and in which

X^1 is $(CHR^7)_g$ or $(CHR^7)_h-Q-(CHR^8)_k$, in which

Q is selected from O, S, $N-R^6$, $(O-CHR^7)_g$, $(CHR^7-O)_g$, $CR^9=CR^{10}$, $(O-CHR^9CHR^{10})_g$, $(CHR^9CHR^{10}-O)_g$, C=O, C=S, $C=NR^6$, $CH(OR^6)$,

C(OR⁶)(OR⁶), C(=O)O, OC(=O), OC(=O)O, C(=O)N(R⁶),
 N(R⁶)C(=O), OC(=O)N(R⁶), N(R⁶)C(=O)O, CH=N-O, CH=N-NR⁶,
 OC(O)NR⁶, NR⁶C(O)O, S=O, SO₂, SO₂NR⁶ and NR⁶SO₂,

g is 1, 2, 3, 4, 5 or 6,

h and k, independently of one another, are 0, 1, 2, 3, 4, 5 or 6, and

R⁶ is selected, independently, from H, A or cycloalkyl having from 3 to 7 carbon atoms,

R⁷, R⁸, R⁹ and R¹⁰ are selected, independently, from the meanings indicated for R² to R⁵;

Y is CH, N, COR¹¹, CSR¹¹, an unsubstituted or substituted, spiro-linked carbocyclic radical having from 5 to 7 carbon atoms or an unsubstituted or substituted, spiro-linked, 5-, 6- or 7-membered heterocyclic radical having from 1 to 3 heteroatoms selected from N, S or O,

R¹¹ is H, A, (CH₂)_nHet, (CH₂)_nAr or cycloalkyl having from 3 to 7 carbon atoms,

X² ~~is a bond or is selected, independently, from the meanings indicated for X⁴, and is preferably~~ a bond or O, S, N-R⁷, CH₂ or CH₂CH₂,

p, q and r, independently of one another, are 0, 1, 2 or 3

and

Hal is F, Cl, Br or I, and

~~R¹² and R¹³, independently of one another, are selected from the meanings of R⁴ other than H and are preferably, independently of one another, Hal, CN, NO₂, OR⁶, N(R⁶)₂, NO₂, CN, COOR⁶, CON(R⁶)₂, NR⁶COR⁶, NR⁶CON(R⁶)₂, NR⁶SO₂A, COR⁶, SO₂NR⁶, S(O)_wA, OOCR⁶ and/or C(NH)NOH,~~

~~and or a pharmaceutically usable derivatives, salts, solvates and stereoisomers and mixtures acceptable salt, solvate, stereoisomer or mixture thereof.~~

Claim 4. (Currently Amended) Compounds A compound ~~according to Claim 1, selected from of the formula~~

- a) 6-{3-[4-(4-fluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;
- b) 6-{3-[4-(2,4-difluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;
- c) 6-{3-[4-(4-fluorophenoxy)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;
- d) 4-{3-[4-(4-fluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;
- e) 4-{3-[4-(2,4-difluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;
- f) 4-{3-[4-(4-fluorophenoxy)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;
- g) 5-{3-[4-(4-fluorophenoxy)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;
- h) 5-{3-[4-(4-fluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;
- i) 5-{3-[4-(2,4-difluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;
- j) 5-{3-[4-(4-cyanophenyl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;
- k) 5-{4-[3-(3-cyano-1H-indol-6-yl)propyl]piperazin-1-yl}benzofuran-2-carboxamide;
- l) 5-{3-[4-(2-oxo-2H-chromen-6-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;

- m) 5-{4-[3-(3-cyano-1H-indol-4-yl)propyl]piperazin-1-yl}-benzofuran-2-carboxamide;
- n) 5-{4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazin-1-yl}-benzofuran-2-carboxamide;
- o) 5-{3-[4-(1H-indol-4-yl)-piperazin-1-yl]propyl}-1-methanesulfonyl-1H-indole-3-carbonitrile;
- p) 5-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]-1H-indole-3-carbonitrile;
- q) 5-[3-(4-benzo[1,2,5]thiadiazol-4-yl)piperazin-1-yl]propyl]-1H-indole-3-carbonitrile;
- r) 3-{1-[3-(3-cyano-1H-indol-5-yl)propyl]piperidin-4-yl}-1H-indole-5-carboxamide;
- s) 5-[3-(4-quinolin-8-yl)piperazin-1-yl]propyl]-1H-indole-3-carbonitrile;
- t) 5-[3-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]propyl]-1H-indole-3-carbonitrile;
- u) 1-methanesulfonyl-5-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]-1H-indole-3-carbonitrile;
- v) 5-{3-[4-(1H-indol-4-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;
- w) 5-{3-[4-(1H-indol-3-yl)piperidin-1-yl]propyl}-1H-indole-3-carbonitrile;
- x) 5-{3-[4-(5-fluoro-1H-indol-3-yl)piperidin-1-yl]propyl}-1H-indole-3-carbonitrile;
- y) 3-{1-[3-(3-cyano-1H-indol-5-yl)propyl]piperidin-4-yl}-1H-indole-5-carbonitrile;
- z) 5-{3-[4-(6-fluoro-1H-indol-3-yl)piperidin-1-yl]propyl}-1H-indole-3-carbonitrile;
- aa) 5-{3-[4-(4-fluoro-1H-indol-3-yl)piperidin-1-yl]propyl}-1H-indole-3-carbonitrile;
- bb) 5-[3-(4-benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-1H-indole-3-carbonitrile;
- cc) 4-{1-[3-(3-cyano-1H-indol-6-yl)propyl]piperidin-4-yloxy}benzamide;
- dd) 6-[3-[4-(2-cyano-3-methoxyphenyl)piperazin-1-yl]propyl]-1H-indole-3-


- carbonitrile;
- ee) 6-{3-[4-(4-cyano-3-methoxyphenyl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;
- ff) 6-{3-[4-(4-cyano-2-methoxyphenyl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;
- gg) 4-[3-(4-pyrazol-1-ylmethyl-1-piperidyl)propyl]-1H-indole-3-carbonitrile;
- hh) N-(6-{4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazin-1-yl}-2-oxo-2H-chromen-3-yl)acetamide;
- ii) 5-{3-[(pyridin-3-ylmethyl)amino]propyl}-1H-indole-3-carbonitrile;
- jj) 5-{3-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;
- kk) 5-[3-(4-pyrimidin-2-ylpiperazin-1-yl)propyl]-1H-indole-3-carbonitrile;
- ll) 5-{3-[(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)amino]propyl}-1H-indole-3-carbonitrile;
- mm) 5-{3-[4-(3-methoxyphenyl)-3-methylpiperazin-1-yl]propyl}-1H-indole-3-carbonitrile;
- nn) 5-{3-[4-(1-methyl-1H-imidazo[4,5-c]pyridin-4-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;
- oo) N-(4-{1-[3-(3-cyano-1H-indol-5-yl)propyl]piperidin-4-ylmethyl}phenyl)acetamide;
- pp) 5-{3-[4-(4-pyridin-3-ylthiazol-2-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;
- qq) ethyl 2-{4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazin-1-yl}-thiazole-4-carboxylate;
- rr) 5-{3-[3-(2-oxopyrrolidin-1-yl)propylamino]propyl}-1H-indole-3-carbonitrile;
- ss) ethyl (6-{4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazin-1-yl}-2-oxo-2H-chromen-3-yl)carbamate;
- tt) 5-{3-[4-(3-amino-2-oxo-2H-chromen-6-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;
- uu) methyl (6-{4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazin-1-yl}-2-oxo-

- 2H-chromen-3-yl)carbamate;
- vv) 2-{4-[3-(3-cyano-1H-indol-5-yl)propyl]-piperazin-1-yl}thiazole-4-carboxamide;
- ww) 4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazine-1- thiocarboxamide;

and derivatives, salts and solvates or a pharmaceutically acceptable salt, solvate, stereoisomer or mixture thereof.

Claim 5. (Currently Amended) ~~Process~~ A process for the preparation of compounds a compound of the formula I according to Claim 1 ~~and salts~~ or a salt thereof, characterised in that comprising reacting


- a) a compound of the formula II



in which

L^1 is Cl, Br, I, OH, a reactively esterified OH group or a diazonium group, and R^1 , D, E, R^{12} , p and X^1 are as defined in Claim 1,

- b) ~~is reacted~~ with a compound of the formula III



in which

L^2 is H or a metal ion, and E, G, X^2 and Z are as defined in Claim 1,

and optionally

- c) converting the resultant compound of the formula I ~~is converted~~ into ~~one of its salts~~ a salt by treatment with an acid.

Claim 6. (Currently Amended) ~~Process~~ A process for the preparation of a pharmaceutical composition, ~~characterised in that~~ comprising converting a compound of the formula I according to Claim 1 and/or one of its ~~a physiologically acceptable salts~~ is converted into a suitable dosage form together with at least one solid, liquid or semi-liquid excipient or adjuvant.

Claim 7. (Currently Amended) ~~Pharmaceutical~~ A pharmaceutical composition, characterised by a content of comprising at least one compound of the formula I according to Claim 1 and/or one of its physiologically acceptable salts and/or one of its solvates and a pharmaceutically acceptable carrier.

Claim 8. (Cancelled)

Claim 9. (Currently Amended) ~~Compounds of the formula I according to Claim 1 and/or physiologically acceptable salts thereof as~~ A method for modulating the activity of an excitatory amino acid antagonists in a cell, comprising contacting said cell with a compound of claim 1.

Claim 10. (Currently Amended) ~~Compounds of the formula I according to Claim 1 and physiologically acceptable salts and solvates thereof as~~ A method for modulating the activity of a glycine transporter inhibitor comprising contacting said transporter with a compound of claim 1.

Claim 11. (Currently Amended) ~~Compounds of the formula I according to Claim 1 and physiologically acceptable salts thereof as~~ A method according to claim 9 wherein said compound antagonizes the activity of said excitatory amino acid

antagonists for combating neurodegenerative diseases, including cerebrovascular diseases, epilepsy, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, cerebral ischaemia, infarction or psychoses.

Claim 12. (Currently Amended) ~~Use of the compounds of the formula I according to Claim 1 for the preparation of a medicament for the prophylaxis and/or therapy of~~ A method for preventing or treating a 5HT-mediated disease diseases in which 5HT plays a role comprising administering to a host in need thereof a compound of claim 1.

Claim 13. (Currently Amended) ~~Use of the compounds of the formula I corresponding~~ A method according to Claim 12, characterised in that the diseases are wherein said disease is selected from the group comprising depression, strokes, cerebral ischaemia, extrapyramidal motor side effects of neuroleptics and of Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, brain and spinal cord trauma, obsessive-compulsive disorder, sleeping disorders, tardive dyskinesia, learning disorders, age-related memory disorders, eating disorders, such as bulimia, and/or sexual dysfunctions.

Claim 14. (Currently Amended) ~~Use of compounds of the formula I according to Claim 1 and/or physiologically acceptable salts or solvates thereof for the preparation of a medicament for the prophylaxis and/or treatment of~~ A method for treating and/or preventing schizophrenia, depression, dementia, Parkinson's disease, Alzheimer's disease, Lewy bodies dementia, Huntington's disease, Tourette's syndrome, anxiety, learning and memory impairments, neurodegenerative diseases, and other cognitive impairments, as well as nicotine dependence and or pain comprising administering to a host in need thereof a compound of claim 1.


Claim 15. (Currently Amended) ~~Use of the compounds of the formula I according to Claim 1 and/or physiologically acceptable salts thereof for the preparation of a medicament~~ A method for combating neurodegenerative diseases, including cere-

brovascular diseases, epilepsy, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, cerebral ischaemia, infarction or psychoses comprising administering to a host in need thereof a compound of claim 1.

Claim 16. (Currently Amended) ~~Use of the compounds of the formula I according to Claim 1 and/or physiologically acceptable salts thereof~~ A method for combating neurodegenerative diseases, including cerebrovascular diseases, epilepsy, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, cerebral ischaemia, infarction or psychoses comprising administering to a host in need thereof a pharmaceutical composition of claim 7.

Claim 17. (Cancelled)


Claim 18. (Withdrawn, Currently Amended) Compounds A compound of the formula II



in which

L¹ is Cl, Br, I, OH, a reactively esterified OH group or a diazonium group, and R¹, D, E, R¹², p and X¹ are as defined in Claim 1.


Claim 19. (Withdrawn, Currently Amended) Compounds A compound of the formula III



in which

L^2 is H or a metal ion, and E, G, X^2 and Z are as defined in Claim 1.

Claim 20. (New) A compound of the formula Ia



wherein

R^1 is H, A or SO_2A

A is straight-chain or branched alkyl having from 1 to 10 carbon atoms, alkenyl having from 2 to 10 carbon atoms or alkoxyalkyl having from 2 to 10 carbon atoms, and

D-E $R^2C=CR^4$, wherein R^2 is H or methyl and R^4 is CN

X^1 is $(CHR^7)_g$

g is 1, 2, 3, 4, 5 or 6,

R^7 is selected, independently, from the meanings indicated for R^2 to R^5 ;

Y is CH or N,


q is 0,

p and r are, independently of one another, 0, 1, 2 or 3

Hal is F, Cl, Br or I,

R^{12} and R^{13} , independently of one another, are selected from the meanings of R^4 other than H and are, independently of one another, Hal, CN, NO_2 , OR^6 , $N(R^6)_2$, NO_2 , CN, $COOR^6$, $CON(R^6)_2$, NR^6COR^6 , $NR^6CON(R^6)_2$, NR^6SO_2A , COR^6 , SO_2NR^6 , $S(O)_wA$, $OOCR^6$ and/or $C(NH)NOH$, and

X^2-Z is selected from the group consisting of



in which

X^2 is a bond,

R^{14} is selected, independently, from Hal, A, $(CH_2)_nHet$, $(CH_2)_nAr$, $(CH_2)_nCOO(CH_2)_mAr$, $(CH_2)_nCOO(CH_2)_mHet$, $(CH_2)_nOR^6$, $(CH_2)_nO(CH_2)_mAr$, $(CH_2)_nO(CH_2)_mHet$, $(CH_2)_nN(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)(CH_2)_mHet$, $(CH_2)_nSO_2N(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)SO_2(CH_2)_mAr$, $(CH_2)_nSO_2N(R^6)(CH_2)_mHet$, $(CH_2)_nN(R^6)SO_2(CH_2)_mHet$, $(CH_2)_nN(R^6)_2$, $(CH_2)_nNHOA$, $(CH_2)_n(R^6)Het$, $(CH_2)_nOCOR^6$, $(CH_2)_nOC(O)N(R^6)_2$, $(CH_2)_nOC(O)NR^6(CH_2)_mAr$, $(CH_2)_nOC(O)NR^6(CH_2)_mHet$, $(CH_2)_nNR^6COOR^6$, $(CH_2)_nNR^6COO(CH_2)_mAr$, $(CH_2)_nNR^6COO(CH_2)_mHet$,


w is 0, 1, 2 or 3,

t is 0, 1, 2, 3, 4 or 5, and


R' is H, A, $(CH_2)_nHet$, $(CH_2)_nAr$, cycloalkyl having from 3 to 7 carbon atoms or SO_2A ;

or a pharmaceutically salt, solvate, stereoisomer, or mixture thereof.


Claim 21. (New) A compound of the formula IIa



wherein R^1 and R^2 are as defined in claim 20; and
Y-Z is a radical of the formulae




or a radical of the formulae



or a pharmaceutically salt, solvate, stereoisomer, or mixture thereof.

Claim 22. (New)

A compound of the formula Ia according to claim 20



wherein

R^1 is H or A

A is straight-chain or branched alkyl having from 1 to 10 carbon atoms, alkenyl having from 2 to 10 carbon atoms or alkoxyalkyl having from 2 to 10 carbon atoms, and

D-E $R^2C=CR^4$, wherein R^2 is H or methyl and R^4 is CN

X^1 is $(CHR^7)_g$

g is 3,

R^7 is selected, independently, from the meanings indicated for R^2 to R^5 ;

Y is CH or N,


q is 0,

p and r are, independently of one another, 0, 1, 2 or 3

Hal is F, Cl, Br or I,

R^{12} and R^{13} , are, independently of one another, Hal, CN, NO_2 , OR^6 , $N(R^6)_2$, NO_2 , CN, $COOR^6$, $CON(R^6)_2$, NR^6COR^6 , $NR^6CON(R^6)_2$, NR^6SO_2A , COR^6 , SO_2NR^6 , $S(O)_wA$, $OOCR^6$ and/or $C(NH)NOH$, and

X^2-Z is selected from the group consisting of



in which

X^2 is a bond,

R^{14} is selected, independently, from Hal, NO_2 , OR^6 , $N(R^6)_2$, CN, $COOR^6$, $CON(R^6)_2$, NR^6COR^6 , $NR^6CON(R^6)_2$, NR^6SO_2A , COR^6 , SO_2NR^6 , $S(O)_wA$, $OOCR^6$ and/or $C(NH)NOH$,

w is 0, 1, 2 or 3,

t is 1, 2, 3, and

R' is H, A, $(CH_2)_nHet$, $(CH_2)_nAr$, cycloalkyl having from 3 to 7 carbon

atoms or SO₂A;
or a pharmaceutically salt, solvate, stereoisomer, or mixture thereof.